Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Tenaya Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
31.1
54.4
94.5
98
86.7
68.6
General and administrative
7.81
18.4
31.1
33.2
29.2
24.7
Operating expenses
38.9
72.8
126
131
116
93.3
Operating income
-38.9
-72.8
-126
-131
-116
-93.3
Interest income
0.09
0.11
1.95
7.06
4.74
2.68
Other non-operating income
0.52
0.09
1.96
7.11
4.82
2.73
Pre-tax income
-38.4
-72.7
-124
-124
-111
-90.6
Income tax
0
0
0
0
0
0
Net income
-38.4
-72.7
-124
-124
-111
-90.6
EBITDA
-36.4
-69.8
-119
-123
-107
-84.9
EPS, basic
-39.50
-4.10
-2.76
-1.68
-1.31
-0.59
EPS, diluted
-39.50
-4.10
-2.76
-1.68
-1.31
-0.59
Shares, basic (weighted)
0.97
17.7
44.8
73.8
84.8
153
Shares, diluted (weighted)
0.97
17.7
44.8
73.8
84.8
153
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
129
38.1
95.3
45.7
4.32
101
Short-term investments
213
91.3
59
57.1
Other current assets
1.43
4.06
0.94
1.16
0.84
1.03
Total current assets
130
255
194
112
67.4
106
Property, plant and equipment
17.2
43
51
43.3
35.9
27.7
Lease right-of-use assets
11.7
11.7
9.98
11.9
9.42
Long-term investments
17.7
Other non-current assets
0.47
4.13
4.79
5.68
4.82
4.25
Total assets
148
314
279
171
120
147
Accounts payable
1.02
10.7
9.58
5.63
5.16
3.58
Accrued liabilities
3.16
9.06
10.7
12.8
8.04
8.84
Total current liabilities
5.04
21.8
24.2
22.7
16
15.4
Lease liabilities
13.7
11.1
8.11
10.8
7.81
Other non-current liabilities
0.02
0.18
0.23
0.25
0.28
0.41
Total liabilities
8.72
35.7
35.6
31.1
27.1
23.7
Paid-in capital
1.58
434
523
543
607
728
Retained earnings
-82.8
-156
-279
-403
-514
-605
Other comprehensive income
-0.14
-0.38
-0.11
0.03
0
Shareholders' equity
-81.3
279
243
139
92.9
123
Total equity
-81.3
279
243
139
92.9
123
Total liabilities and equity
148
314
279
171
120
147
Shares outstanding
1.21
41.3
66.9
68.3
86.5
217
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-38.4
-72.7
-124
-124
-111
-90.6
Depreciation and amortization
2.48
2.96
6.47
8.69
8.47
8.44
Stock-based compensation
0.74
2.95
11.5
15.3
16.5
13
Change in payables
0.14
8.6
1.66
-3.28
-0.58
-1.43
Cash from operations
-35.4
-60.8
-104
-102
-90.5
-68.3
Capital expenditures
-9.76
-25.1
-20.6
-1.24
-1.03
-0.62
Purchases of investments
-213
-140
-56.6
-87.1
0
Sales and maturities of investments
2.75
245
107
81.2
45.7
Cash from investing
-7.01
-239
83.7
48.7
1.13
56.1
Stock issued
0.03
0.37
3.87
Share buybacks
-0
-0.01
Cash from financing
147
209
77.8
4.05
47.7
108
Net change in cash
105
-90.4
57
-49.3
-41.6
96.2
Free cash flow
-45.2
-85.9
-125
-103
-91.5
-68.9
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.61 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-148.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-110.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
32.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-20.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
22.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-19.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-0.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
80.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
50.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
175.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.52x
Current assets / current liabilities.
Quick ratio
4.12x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.11x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.24
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.24
Cash from operations / diluted weighted shares.
Book value per share
$0.31
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.97x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.97x
Market cap / tangible book value, when positive.
FCF yield
-38.4%
Free cash flow / market cap.
Earnings yield
-75.4%
Net income / market cap (the inverse of P/E).
Was Tenaya Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $90.6M.
How much free cash flow did Tenaya Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $68.3M minus capital expenditures of $618.0K left free cash flow of -$68.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.